CLS presents study results and board changes
Despite CLS’ decision to focus on commercialisation within neurosurgery, the company continues to present study results supporting the use of the TRANBERG system for the treatment of prostate cancer. Meanwhile, the company has announced a change in the board – Lars-Erik Eriksson, board member, former CEO, and co-founder, has decided to step down from his position.
Medtech company Clinical Laserthermia Systems (CLS) has developed two systems – the TRANBERG Thermal Therapy System and the ClearPoint Prism Neuro Laser Therapy System – for minimally invasive focal laser ablation treatment of cancer tumors and drug-resistant epilepsy. These systems enable precision treatment with high efficiency and minimal impact on surrounding tissue.
The company has initiated the commercialisation of the ClearPoint Prism system for treating brain tumors and epilepsy in collaboration with its partner, ClearPoint Neuro. Alongside this, the initiatives in prostate cancer treatment with TRANBERG have been paused, as the company has chosen to focus on the neurosurgery segment to optimize costs and improve profitability.
Results published in scientific journal
However, progress with TRANBERG continues. The company recently presented results from an investigator-initiated study conducted at Radboud University Medical Center. The aim of the study was to evaluate the feasibility and safety of MR-guided laser ablation using TRANBERG in combination with the Thermoguide Workstation for precise ablation control.
The study results have now been published in a scientific article in the Journal of Vascular and Interventional Radiology. The findings indicate a good oncological response, and technical success in all 10 prostate cancer patients with low to intermediate risk. Two patients had residual and recurrent disease at the treatment site during follow-up, which aligns with previous studies on MR-guided focal laser ablation.
Controlled laser ablation
No significant changes in urinary or sexual function were reported after 12 months, suggesting that laser ablation with the TRANBERG system can provide a favorable oncological control without the side effects commonly associated with radical treatments, such as incontinence and erectile dysfunction.
The study highlights that laser ablation may provide several advantages over other energy sources in the treatment of prostate cancer, as prostate tissue naturally has a high optical absorption rate. It also emphasizes the benefits of MR guidance and the use of CLS Thermoguide software for real-time temperature feedback, ensuring precise tumor ablation with high accuracy and control.
Co-founder leaves the board
Before the weekend, the company announced that co-founder and former CEO Lars-Erik Eriksson is leaving the board at his own request. Lars-Erik founded CLS in 2006 together with Karl-Göran Tranberg and Pär Henriksson and has since played a central role in the company’s development.
– We are grateful to Lars-Erik for everything he has done for CLS, says Peter Max, Chairman of the Board of CLS.
– His leadership and passion for innovation have been crucial to the company’s development.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
